Leap Therapeutics And MacroGenics Among Early Winners And Losers At ESMO

Contrasting Market Reception For Rivals In GI Cancer

 
• By Andrew McConaghie
Concerns about safety and tough competition in the oncology market weighed on MacroGenics shares.

More from Business

More from Scrip